Flex Pharma (FLKS) Reports Q4 Loss of $0.46/Share

Go back to Flex Pharma (FLKS) Reports Q4 Loss of $0.46/Share

Flex Pharma Reports Year End 2017 Financial Results

March 7, 2018 7:00 AM EST

-- FLX-787 Exploratory MS Spasticity Results at the end of March --

-- FLX-787 Phase 2 ALS & CMT Clinical Studies Ongoing --

-- Cash to Mid 2019 --

Conference Call Scheduled Today at 9:00 a.m. ET

BOSTON--(BUSINESS WIRE)-- Flex... More